11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 27.03.2026 Expectation: 10000 pips
Silver consolidates below resistance
Today at 10:32 AM 21
Period: 20.03.2026 Expectation: 1390 pips
AUDCAD pullback offers buying opportunity ahead of expected RBA hike
Today at 10:03 AM 17
Brent sell
Period: 30.04.2026 Expectation: 1500 pips
New play for Brent crude is to sell from $110 per barrel
Today at 09:23 AM 11
Period: 31.12.2026 Expectation: 5000 pips
Selling SPX down to $6,200
Today at 09:23 AM 12
Period: 20.03.2026 Expectation: 1100 pips
GBPUSD is on verge of breaching support amid global flight into dollar
Today at 09:11 AM 15
Period: 20.03.2026 Expectation: 500 pips
Buying Brent crude with $105 in view
Today at 07:49 AM 17
Go to forecasts